ONCT240719P2500
- 0.00
- 0.000.00%
Oncternal Therapeutics Newsroom
Express News | Oncternal Therapeutics, Inc. : H.c. Wainwright Cuts Target Price to $19 From $28
Oncternal Therapeutics | 10-Q: Quarterly report
Express News | Oncternal Therapeutics- Cash, Cash Equivalents and Short-Term Investments Totaled $27.0 Mln as of March 31, 2024; Cash Runway Projected Into Q1 2025
Oncternal Therapeutics 1Q Rev $569,000 >ONCT
Oncternal Therapeutics 1Q Rev $569,000 >ONCT
Express News | Oncternal Therapeutics Q1 Operating Expenses USD 9.348 Million
Express News | Oncternal Therapeutics Q1 Income From Operations USD -8.779 Million
Express News | Oncternal Therapeutics Q1 Basic EPS USD -2.83
Oncternal Therapeutics to Provide Business Update and Report First Quarter 2024 Financial Results
SAN DIEGO, May 02, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (NASDAQ:ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will
Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, May 01, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today anno
Express News | Oncternal Announces First Patient Dosed in Fourth Cohort of Phase 1/2 Study of Onct-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
Oppenheimer Reaffirms Their Hold Rating on Oncternal Therapeutics (ONCT)
Oncternal Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Oncternal Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Oncternal Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/15/2024 197.87% HC Wainwright & Co. $30 → $28 Maintains Buy 01/29/2024 219.15% HC Wainwright & Co. $2 →
Express News | Oncternal Therapeutics, Inc. : H.c. Wainwright Cuts Target Price to $28 From $30
AIVITA Biomedical CEO Dr. Hans Keirstead and CMO Dr. Robert Dillman to Speak and Participate in Keynote Panel at Festival of Biologics USA
IRVINE, Calif., April 11, 2024 /PRNewswire/ -- AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, today announced that chief executive officer Hans Keirstea
Oncternal Therapeutics(ONCT.US) Director Buys US$27,654.57 in Common Stock
$Oncternal Therapeutics(ONCT.US)$ Director Wills Robert James purchased 3,086 shares of common stock on Apr 8, 2024 at an average price of $8.9613 for a total value of $27,654.57.Source: Announcement
Insiders Buying Westlake Chemical Partners And 2 Other Stocks
Although U.S. stocks closed mostly lower on Monday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company's prospects or that they view t
Oncternal Therapeutics(ONCT.US) Director Buys US$58,602.37 in Common Stock
$Oncternal Therapeutics(ONCT.US)$ Director Wills Robert James purchased 6,914 shares of Common Stock on Mar 28, 2024 at an average price of $8.4759 for a total value of $58,602.37.Source: Announcement
Oncternal Participating in Virtual Fireside Chat With Key Opinion Leader on Treatment Landscape & New Treatment Options for Prostate Cancer
SAN DIEGO, March 15, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (NASDAQ:ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced it will
Oncternal Therapeutics Full Year 2023 Earnings: Revenues Beat Expectations, EPS In Line